Breaking News Instant updates and real-time market news.

TODAY'S FREE FLY STORIES

Options
Notable open interest changes for July 2nd » 08:55
07/02/20
07/02
08:55
07/02/20
08:55
APA

Apache

$12.99 /

-0.52 (-3.85%)

, DXC

DXC Technology

$16.13 /

-0.425 (-2.57%)

, SCHW

Charles Schwab

$33.03 /

-0.7 (-2.08%)

, PCG

PG&E

$9.03 /

+0.16 (+1.80%)

Wednesday's total…

Wednesday's total option volume of 25.5 million contracts resulted in net open interest growth of 3.21 million calls and 2.79 million puts. Apache (APA), DXC Technology (DXC), Charles Schwab (SCHW) and PG&E (PCG) saw the greatest growth. Top five new positions opened include 116k Apache (APA) 8/7 weekly 13 puts, 115k Apache (APA) 8/7 weekly 14 calls, 94k DXC Technology (DXC) Aug-20 17 calls, 93k DXC Technology (DXC) Aug-20 16 puts and 90k Charles Schwab (SCHW) 8/7 weekly 34.5 calls.

ShowHide Related Items >><<
SCHW Charles Schwab
$33.03 /

-0.7 (-2.08%)

PCG PG&E
$9.03 /

+0.16 (+1.80%)

DXC DXC Technology
$16.13 /

-0.425 (-2.57%)

APA Apache
$12.99 /

-0.52 (-3.85%)

APA Apache
$12.99 /

-0.52 (-3.85%)

06/19/20 Mizuho
Apache price target raised to $17 from $10 at Mizuho
06/15/20 Citi
Apache upgraded to Buy from Neutral at Citi
04/08/20 SunTrust
Apache price target lowered to $10 from $22 at SunTrust
03/31/20 UBS
Apache upgraded to Neutral from Sell at UBS
DXC DXC Technology
$16.13 /

-0.425 (-2.57%)

06/01/20 BMO Capital
DXC Technology price target lowered to $16 from $42 at BMO Capital
05/29/20
Fly Intel: Top five analyst downgrades
05/29/20 JPMorgan
JPMorgan downgrades DXC to Neutral on dividend suspension
05/29/20 JPMorgan
DXC Technology downgraded to Neutral from Overweight at JPMorgan
SCHW Charles Schwab
$33.03 /

-0.7 (-2.08%)

06/08/20 Wolfe Research
TD Ameritrade downgraded to Underperform from Outperform at Wolfe Research
06/08/20 Wolfe Research
Charles Schwab downgraded to Underperform from Outperform at Wolfe Research
05/21/20 BofA
Charles Schwab downgraded to Neutral from Buy at BofA
05/21/20 BofA
Charles Schwab downgraded to Neutral from Buy at BofA
PCG PG&E
$9.03 /

+0.16 (+1.80%)

06/24/20 Vertical Research
PG&E initiated with a Buy at Vertical Research
06/23/20 Seaport Global
PG&E initiated with a Neutral at Seaport Global
06/10/20 Barclays
PG&E price target raised to $16 from $15 at Barclays
06/09/20 Morgan Stanley
PG&E updated financing plan offers less downside risk, says Morgan Stanley
SCHW Charles Schwab
$33.03 /

-0.7 (-2.08%)

PCG PG&E
$9.03 /

+0.16 (+1.80%)

DXC DXC Technology
$16.13 /

-0.425 (-2.57%)

APA Apache
$12.99 /

-0.52 (-3.85%)

  • 26
    Jun
SCHW Charles Schwab
$33.03 /

-0.7 (-2.08%)

PCG PG&E
$9.03 /

+0.16 (+1.80%)

DXC DXC Technology
$16.13 /

-0.425 (-2.57%)

APA Apache
$12.99 /

-0.52 (-3.85%)

SCHW Charles Schwab
$33.03 /

-0.7 (-2.08%)

PCG PG&E
$9.03 /

+0.16 (+1.80%)

DXC DXC Technology
$16.13 /

-0.425 (-2.57%)

APA Apache
$12.99 /

-0.52 (-3.85%)

SCHW Charles Schwab
$33.03 /

-0.7 (-2.08%)

PCG PG&E
$9.03 /

+0.16 (+1.80%)

DXC DXC Technology
$16.13 /

-0.425 (-2.57%)

APA Apache
$12.99 /

-0.52 (-3.85%)

Conference/Events
Genworth to hold a conference call » 08:55
07/02/20
07/02
08:55
07/02/20
08:55
GNW

Genworth

$2.23 /

-0.08 (-3.47%)

President & CEO…

President & CEO McInerney discusses the Company's recently announced merger extension and 15th waiver and agreement with China Oceanwide Holdings Group on a conference call to be held on July 2 at 9 am. Webcast Link

ShowHide Related Items >><<
GNW Genworth
$2.23 /

-0.08 (-3.47%)

GNW Genworth
$2.23 /

-0.08 (-3.47%)

GNW Genworth
$2.23 /

-0.08 (-3.47%)

GNW Genworth
$2.23 /

-0.08 (-3.47%)

Periodicals
HollyFrontier, CVR Refining cut U.S. refinery jobs, Reuters reports » 08:54
07/02/20
07/02
08:54
07/02/20
08:54
HFC

HollyFrontier

$27.71 /

-1.6 (-5.46%)

, CVI

CVR Energy

$19.06 /

-1.07 (-5.32%)

CVR Refining (CVI) and…

CVR Refining (CVI) and HollyFrontier (HFC) have both cut their workforces in recent weeks amid declining demand due to the ongoing coronavirus pandemic, Reuters' Laura Sanicola reports, citing three sources. According to the sources, CVR Refining has laid off approximately 50 salaried employees and HollyFrontier has cut at least 12 jobs, Reference Link

ShowHide Related Items >><<
HFC HollyFrontier
$27.71 /

-1.6 (-5.46%)

CVI CVR Energy
$19.06 /

-1.07 (-5.32%)

HFC HollyFrontier
$27.71 /

-1.6 (-5.46%)

06/30/20 Cowen
HollyFrontier downgraded to Underperform at Cowen
06/30/20 Cowen
HollyFrontier downgraded to Underperform from Market Perform at Cowen
06/12/20
Fly Intel: Top five analyst downgrades
06/11/20 Goldman Sachs
HollyFrontier downgraded to Sell from Neutral at Goldman Sachs
CVI CVR Energy
$19.06 /

-1.07 (-5.32%)

04/14/20
Fly Intel: Top five analyst upgrades
04/14/20 Scotiabank
CVR Energy upgraded to Sector Perform from Underperform at Scotiabank
03/29/20 Credit Suisse
CVR Energy downgraded to Underperform with $16 target at Credit Suisse
03/27/20 Credit Suisse
CVR Energy downgraded to Underperform from Neutral at Credit Suisse
HFC HollyFrontier
$27.71 /

-1.6 (-5.46%)

CVI CVR Energy
$19.06 /

-1.07 (-5.32%)

HFC HollyFrontier
$27.71 /

-1.6 (-5.46%)

HFC HollyFrontier
$27.71 /

-1.6 (-5.46%)

Hot Stocks
Conduent granted patents designed to optimize schedules, trip planning » 08:54
07/02/20
07/02
08:54
07/02/20
08:54
CNDT

Conduent

$2.35 /

-0.04 (-1.68%)

Conduent Transportation…

Conduent Transportation announced the award of patents designed to optimize schedules and trip planning for public transportation systems that aim to improve the commuting experience. Both patents cover features of the Conduent Mobility Analytics Platform. The Conduent Mobility Analytics Platform aggregates and analyzes urban travel data to better understand user habits and to improve their experience. Using advanced data modeling capabilities across transport operations such as ticketing and fleet management, the platform can optimize the timing and predictability of travel schedules. The platform will also simulate the impacts of planned modifications such as new routes or fare policies. The Conduent Mobility Analytics Platform is a tool aimed at improving travelers' experience. The two new technology patents protect Conduent's intellectual property that enable this functionality, creating "smarter public transportation systems" currently adopted by several cities in Europe. The first patent, "Goal-based Travel Reconstruction," uses a computerized system for tracking passengers who make multi-segment trips, including transfers, to reconstruct their full journeys. Presently, most transit systems only track when passengers board and not when they disembark. This technology uses boarding records and other data to reconstruct the journey and generate insights that can be used to optimize schedules across all segments of a commute. The second patent, "Efficient Optimization of Schedules in a Public Transportation System," employs methods and systems for optimizing passenger transfers from one train, bus or transit line to another. The technology evaluates current schedules and precisely quantifies and models transfer times. Using ticket validation data to construct a realistic scenario-based model of the times, this approach can dynamically adjust the current schedules to reduce the overall expected wait time.

ShowHide Related Items >><<
CNDT Conduent
$2.35 /

-0.04 (-1.68%)

CNDT Conduent
$2.35 /

-0.04 (-1.68%)

04/14/20 JPMorgan
JPMorgan downgrades Conduent to Neutral with turnaround 'stretched' by pandemic
04/13/20 JPMorgan
Conduent downgraded to Neutral from Overweight at JPMorgan
08/28/19 Citi
Citi transfers Conduent at Neutral, cuts price target to $7.50
08/09/19 JPMorgan
Conduent upgraded to Overweight at JPMorgan, price target lowered to $8
CNDT Conduent
$2.35 /

-0.04 (-1.68%)

Recommendations
Hologic price target raised to $64 from $60 at Needham » 08:53
07/02/20
07/02
08:53
07/02/20
08:53
HOLX

Hologic

$56.97 /

-0.12 (-0.21%)

Needham analyst Mike…

Needham analyst Mike Matson raised the firm's price target on Hologic to $64 from $60 and keeps a Buy rating on the shares. The analyst notes that according to the findings of the FDA's latest monthly Mammography Quality Standards Act statistics, the number of digital breast tomosynthesis units fell 27.7% from last year to 68 during June, though their facility penetration rising to 71.0% from 70.6%. Matson adds that his increased price target on Hologic reflects peer multiple expansion.

ShowHide Related Items >><<
HOLX Hologic
$56.97 /

-0.12 (-0.21%)

HOLX Hologic
$56.97 /

-0.12 (-0.21%)

06/30/20 Cowen
Hologic helped by COVID testing, Cowen upgrades to Outperform
06/30/20 Cowen
Hologic upgraded to Outperform from Market Perform at Cowen
06/16/20 BTIG
Hologic price target raised to $60 from $54 at BTIG
06/03/20
Fly Intel: Top five analyst upgrades
HOLX Hologic
$56.97 /

-0.12 (-0.21%)

HOLX Hologic
$56.97 /

-0.12 (-0.21%)

HOLX Hologic
$56.97 /

-0.12 (-0.21%)

Hot Stocks
SuRo Capital sees NAV $11.70-$12.00 per share as of June 30 » 08:52
07/02/20
07/02
08:52
07/02/20
08:52
SSSS

SuRo Capital

$8.66 /

+0.14 (+1.64%)

SuRo Capital Corp.…

SuRo Capital Corp. provided the following preliminary update on its investment portfolio for the second quarter ended June 30, 2020.As previously reported, SuRo Capital's net assets totaled approximately $172.5M, or $10.22 per share, at March 31, 2020, compared to approximately $199.9M, or $11.38 per share as of December 31, 2019. As of June 30, 2020, SuRo Capital's net asset value is estimated to be between $11.70 and $12.00 per share. At June 30, 2020, SuRo Capital held positions in 24 portfolio companies - all privately-held.

ShowHide Related Items >><<
SSSS SuRo Capital
$8.66 /

+0.14 (+1.64%)

SSSS SuRo Capital
$8.66 /

+0.14 (+1.64%)

Periodicals
Spotify may add video streaming features to compete with YouTube, TTL reports » 08:52
07/02/20
07/02
08:52
07/02/20
08:52
SPOT

Spotify

$258.96 /

+0.65 (+0.25%)

, GOOGL

Alphabet Class A

$1,443.21 /

+25.29 (+1.78%)

Spotify (SPOT) is…

Spotify (SPOT) is considering adding video streaming features to its service to compete with Google's (GOOGL) YouTube, Andrei Ene in online tech publication Tech The Lead says, citing sources close to the company. According to a source, Spotify is aiming to provide "curated quality video content that will hopefully attract other creators to the platform." Reference Link

ShowHide Related Items >><<
SPOT Spotify
$258.96 /

+0.65 (+0.25%)

GOOGL Alphabet Class A
$1,443.21 /

+25.29 (+1.78%)

SPOT Spotify
$258.96 /

+0.65 (+0.25%)

07/01/20 Wells Fargo
Spotify price target raised to $175 from $130 at Wells Fargo
06/30/20 Citi
Spotify initiated with a Neutral at Citi
06/29/20
Fly Intel: Top five analyst downgrades
06/29/20 Guggenheim
Guggenheim cuts Spotify to Sell with potential podcast dominance priced in
GOOGL Alphabet Class A
$1,443.21 /

+25.29 (+1.78%)

06/29/20 Stifel
Stifel says Facebook sales won't be materially hurt unless ad boycott broadens
06/25/20 Baird
Alphabet price target raised to $1,650 from $1,500 at Baird
06/24/20 Bernstein
Potential spinoff would be largely positive for VMware, says Bernstein
06/24/20 Goldman Sachs
Alphabet price target raised to $1,775 from $1,425 at Goldman Sachs
SPOT Spotify
$258.96 /

+0.65 (+0.25%)

GOOGL Alphabet Class A
$1,443.21 /

+25.29 (+1.78%)

SPOT Spotify
$258.96 /

+0.65 (+0.25%)

GOOGL Alphabet Class A
$1,443.21 /

+25.29 (+1.78%)

SPOT Spotify
$258.96 /

+0.65 (+0.25%)

GOOGL Alphabet Class A
$1,443.21 /

+25.29 (+1.78%)

SPOT Spotify
$258.96 /

+0.65 (+0.25%)

GOOGL Alphabet Class A
$1,443.21 /

+25.29 (+1.78%)

GOOGL Alphabet Class A
$1,443.21 /

+25.29 (+1.78%)

Hot Stocks
Leaf Group forms Independent Committee to engage with Investor Group » 08:50
07/02/20
07/02
08:50
07/02/20
08:50
LEAF

Leaf Group

$4.04 /

+0.34 (+9.19%)

Leaf Group issued the…

Leaf Group issued the following letter to its shareholders: "Earlier this week, a group of Leaf Group shareholders publicized a letter to the Company's Board of Directors expressing concern with Leaf's business strategy and corporate governance. The Leaf Group Board of Directors will listen to their views and work to engage in a constructive dialogue with them, as we would with any shareholder. Over the past several years, Leaf Group has been focused on executing its strategy of building digital first brands in high passion categories. We have made significant changes across the organization to strengthen our team, optimize our operations and drive much-improved financial performance...On April 15, 2019, we publicly announced the launch of a comprehensive review of all strategic alternatives available to Leaf Group, including a potential sale of the Company, divestitures of certain assets, and various financing alternatives. This review was initiated by the Board at the request of Osmium Partners LLC, with the support of Oak Management and Spectrum Equity, all participants in the Investor Group. Over the next 13 months, a Special Committee of the Board of Directors and its financial and legal advisors assessed an exhaustive range of alternatives to maximize shareholder value. Leaf Group and its advisors contacted over 160 potential acquirers regarding a possible sale of the Company or certain assets and entered into non-disclosure agreements with 45 of those parties to facilitate discussions. Additionally, Leaf Group and its advisors contacted over 48 companies to discuss financing options and engaged in negotiations with parties concerning potential asset sales. This process did not yield a single offer for the whole company, and we received just one offer for one of our assets - a wholly inadequate bid for Society6 Group, which is expected to post its best-ever performance in the second quarter of 2020 with year-over-year Gross Transaction Value growth in excess of 100%. Importantly, two members of the Investor Group-John Hawkins of Generation Partners and Brian Regan of Spectrum Equity- were on Leaf Group's Board of Directors throughout this exhaustive process, and were briefed frequently on it as it developed. Both Mr. Hawkins and Mr. Regan stepped down from the Company's Board in May and April 2020, respectively, a full year into the review process, and were fully aware at the time of their respective resignations that Leaf Group had received no offers for the whole company and just one inadequate offer for Society6 Group. The Board subsequently agreed unanimously to conclude the strategic review process and return the Company's focus to building digital first brands in high-passion categories. The press release announcing the completion and full results of the strategic review process, issued on May 20, can be viewed online here. While the Investor Group is calling for Leaf to conduct this process again, investors should know that the review was comprehensive and clearly reaffirmed that the best path forward to create value for all of Leaf Group's stakeholders is to continue executing on our current business strategy as an independent company. ..Additionally, Leaf Group separately issued a financial update that underscores the Company's strong financial position and performance, even despite uncertain macroeconomic trends. The Company's preliminary second quarter 2020 revenue grew over 35% year-over-year, which would mark the strongest quarterly year-over-year revenue growth rate since the first quarter of 2011 ..Our Board of Directors takes its fiduciary duties to act in the best interests of all of its shareholders extremely seriously, and has accordingly appointed an Independent Committee of Directors comprised of Beverly Carmichael and Deborah Benton to engage with the Investor Group on this topic. These Directors are fully independent and are not investors in, nor have any business or other relationships with any of the members of the Investor Group or our CEO Sean Moriarty. The Independent Committee has sole decision-making power with respect to this matter. The primary focus of the Leaf Group Board of Directors is to ensure the long-term success of the Company by acting in the best interest of all Leaf stakeholders. As always, we welcome shareholder input as part of our ongoing efforts to enhance shareholder value and encourage open and productive dialogues with shareholders to ensure the views and perspectives of all of our investors are evaluated accordingly."

ShowHide Related Items >><<
LEAF Leaf Group
$4.04 /

+0.34 (+9.19%)

LEAF Leaf Group
$4.04 /

+0.34 (+9.19%)

08/06/19 Cowen
Leaf Group downgraded to Market Perform at Cowen
08/06/19 Cowen
Leaf Group downgraded to Market Perform from Outperform at Cowen
LEAF Leaf Group
$4.04 /

+0.34 (+9.19%)

General news
U.S. trade deficit widened 9.7% to -$54.6 B in May » 08:50
07/02/20
07/02
08:50
07/02/20
08:50

U.S. trade deficit…

U.S. trade deficit widened 9.7% to -$54.6 B in May after widening to -$49.8 B (was -$49.4 B) in April. The -$34.7 shortfall in February was a 5-year low. Exports dropped -4.4% after plunging -20.5% in April and -10.2% in March. Imports slipped -0.9% after dropping -13.6% in April (was -13.7%) and -5.6% in March. The real goods balance widened to -$86.5 B from -$80.4 B (was -$80.0 B).

Conference/Events
Generac participates in a webinar with Roth Capital » 08:49
07/02/20
07/02
08:49
07/02/20
08:49
GNRC

Generac

$121.12 /

-0.84 (-0.69%)

Generac CFO Ragen…

Generac CFO Ragen participates in a webinar being held on July 2 at 10 am hosted by Roth Capital.

ShowHide Related Items >><<
GNRC Generac
$121.12 /

-0.84 (-0.69%)

GNRC Generac
$121.12 /

-0.84 (-0.69%)

06/30/20 Roth Capital
Generac initiated with a Buy at Roth Capital
06/25/20 UBS
Generac initiated with a Buy at UBS
05/29/20
Fly Intel: Top five analyst downgrades
05/29/20 Northcoast
Generac downgraded to Neutral from Buy at Northcoast
GNRC Generac
$121.12 /

-0.84 (-0.69%)

Hot Stocks
Leaf Group reports Q2 revenue up 35% y-o-y, two est. $38.22M » 08:47
07/02/20
07/02
08:47
07/02/20
08:47
LEAF

Leaf Group

$4.04 /

+0.34 (+9.19%)

Leaf Group provided a…

Leaf Group provided a financial update. Leaf Group's second quarter 2020 revenue grew over 35% year-over-year, reflecting strong Marketplaces growth through the end of June 2020, partially offset by lower Media revenue. Leaf Group's second quarter 2020 revenue was its highest since fiscal year 2013, driven by its strongest year-over-year revenue growth rate since the first quarter of 2011. Society6 Group Gross Transaction Value increased over 125% year-over-year in the second quarter 2020 driven by overall Direct-to-Consumer GTV growth of over 150%, including over 170% growth in the US and over 75% growth internationally. Society6 Group experienced strong eCommerce demand across all its main categories of Wall Art, Home Decor, and Technology as well as recently-launched Masks on June 23, 2020. Saatchi Art Group GTV increased over 40% year-over-year in the second quarter. This growth was driven by strength in the Saatchi Art Group online marketplace and recently-launched The Other Art Fair Online Studios, partially offset by the postponement or cancellation of five live fairs in the second quarter 2020. Media revenue declined approximately 28% year-over-year in the second quarter 2020, impacted, in part, by the timing of advertising campaigns for certain of our direct advertising clients. As of June 30, 2020, Leaf Group had over $25M in cash and cash equivalents. On April 30, Leaf Group sold a library of content currently displayed on selected Hearst websites to Hearst Newspapers in exchange for $9.5M, of which $4M was paid at signing, and up to an additional $5.5M will be paid upon completion of the content migration, expected to be finalized in the third quarter of 2020.

ShowHide Related Items >><<
LEAF Leaf Group
$4.04 /

+0.34 (+9.19%)

LEAF Leaf Group
$4.04 /

+0.34 (+9.19%)

08/06/19 Cowen
Leaf Group downgraded to Market Perform at Cowen
08/06/19 Cowen
Leaf Group downgraded to Market Perform from Outperform at Cowen
LEAF Leaf Group
$4.04 /

+0.34 (+9.19%)

Recommendations
Overstock.com price target raised to $66 from $33 at DA Davidson » 08:46
07/02/20
07/02
08:46
07/02/20
08:46
OSTK

Overstock.com

$30.08 /

+1.65 (+5.80%)

DA Davidson analyst Tom…

DA Davidson analyst Tom Forte raised the firm's price target on Overstock.com to $66 from $33 and keeps a Buy rating on the shares. The analyst says his new price target reflects an updated stress test of his sum-of-parts analysis, adding that in spite of the strong rebound in shares, he continues to see a lot of value in the stock while assigning $42 per share value to the retail business - up from 9% prior - and unchanged $19 per share value to its tZero business. Forte adds that the retail business has benefited from the improvements that the management has made and from the surge in sales trends related to the pandemic.

ShowHide Related Items >><<
OSTK Overstock.com
$30.08 /

+1.65 (+5.80%)

OSTK Overstock.com
$30.08 /

+1.65 (+5.80%)

05/12/20 Jefferies
Overstock.com 130% sales jump positive for Wayfair, says Jefferies
05/06/20 DA Davidson
Wayfair price target raised to $100 from $45 at DA Davidson
04/13/20 KeyBanc
Overstock hardlines sales up by 254% y/y in week of April 5, says KeyBanc
11/13/19 DA Davidson
Overstock.com price target lowered to $25 from $48 at DA Davidson
OSTK Overstock.com
$30.08 /

+1.65 (+5.80%)

OSTK Overstock.com
$30.08 /

+1.65 (+5.80%)

OSTK Overstock.com
$30.08 /

+1.65 (+5.80%)

Hot Stocks
Alexion to pay more than $21M to resolve SEC FCPA charges » 08:45
07/02/20
07/02
08:45
07/02/20
08:45
ALXN

Alexion

$112.31 /

+0.03 (+0.03%)

The Securities and…

The Securities and Exchange Commission announced that Boston-based pharmaceutical company Alexion Pharmaceuticals has agreed to pay more than $21M to resolve charges that it violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act. According to the SEC's order, two Alexion subsidiaries made payments to foreign government officials to secure favorable treatment for Alexion's primary drug, Soliris. The order finds that, from 2010 to 2015, Alexion Turkey paid Turkish government officials to improperly influence them to approve patient prescriptions and provide other favorable regulatory treatment for Soliris. The order similarly finds that from 2011 to 2015, Alexion Russia made improper payments to Russian government health care officials to favorably influence the regulatory treatment of and the budget allocated to Soliris as well as to increase the number of approved Soliris prescriptions. Alexion's internal accounting controls failed to detect and prevent payments to foreign government officials by its subsidiaries," said Melissa Hodgman, an Associate Director in the SEC's Division of Enforcement. "Companies in frequent contact with foreign officials need to ensure that their internal controls appropriately address such risks." Without admitting or denying the SEC's findings, Alexion agreed to cease and desist from committing violations of the books and records and internal accounting controls provisions of the FCPA and pay $14.2M in disgorgement, $3.78M in prejudgment interest, and a $3.5M penalty.

ShowHide Related Items >><<
ALXN Alexion
$112.31 /

+0.03 (+0.03%)

ALXN Alexion
$112.31 /

+0.03 (+0.03%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
ALXN Alexion
$112.31 /

+0.03 (+0.03%)

ALXN Alexion
$112.31 /

+0.03 (+0.03%)

ALXN Alexion
$112.31 /

+0.03 (+0.03%)

ALXN Alexion
$112.31 /

+0.03 (+0.03%)

General news
U.S. initial jobless claims fell -55k to 1,427k » 08:45
07/02/20
07/02
08:45
07/02/20
08:45

U.S. initial jobless…

U.S. initial jobless claims fell -55k to 1,427k in the week ended June 27 following the -58k drop to 1,482k (was 1,480k) in the week of June 20. It's a 13th straight weekly decline after the surge to a record high of 6,867k in the March 27 week. The 201k on January 31 was the lowest since 197k in the November 14, 1969 week. The 4-week moving average was 1,503.75k from 1,621.25k (was 1,620.75k). Continuing claims were 59k higher at 19,290k in the June 20 week after falling -1,058k to 19,231k (was 19,522k).

Options
Largest borrow rate increases among liquid names » 08:45
07/02/20
07/02
08:45
07/02/20
08:45
MARK

Remark Holdings

$2.30 /

-0.05 (-2.13%)

, APT

Alpha Pro Tech

$17.70 /

-0.05 (-0.28%)

, AMC

AMC Entertainment

$4.56 /

+0.275 (+6.42%)

, BCLI

BrainStorm

$11.21 /

+0.01 (+0.09%)

, BGS

B&G Foods

$24.18 /

-0.23 (-0.94%)

, YCBD

cbdMD

$1.88 /

-0.005 (-0.27%)

, TTNP

Titan Pharmaceuticals

$0.30 /

-0.0085 (-2.80%)

, PEI

Pennsylvania REIT

$1.39 /

+0.03 (+2.21%)

, CRC

California Resources

$1.27 /

+0.045 (+3.69%)

, GRPN

Groupon

$17.50 /

-0.59 (-3.26%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Remark Media (MARK) 190.24% +3.93, Alpha Pro Tech (APT) 57.24% +2.22, AMC Entertainment (AMC) 71.31% +1.92, BrainStorm (BCLI) 70.30% +1.90, B&G Foods (BGS) 12.82% +1.82, cbdMD (YCBD) 24.11% +1.24, Titan Pharmaceuticals (TTNP) 37.01% +0.62, Pennsylvania REIT (PEI) 86.36% +0.49, California Resources (CRC) 270.47% +0.37, and Groupon (GRPN) 0.68% +0.33.

ShowHide Related Items >><<
YCBD cbdMD
$1.88 /

-0.005 (-0.27%)

TTNP Titan Pharmaceuticals
$0.30 /

-0.0085 (-2.80%)

PEI Pennsylvania REIT
$1.39 /

+0.03 (+2.21%)

MARK Remark Holdings
$2.30 /

-0.05 (-2.13%)

GRPN Groupon
$17.50 /

-0.59 (-3.26%)

CRC California Resources
$1.27 /

+0.045 (+3.69%)

BGS B&G Foods
$24.18 /

-0.23 (-0.94%)

BCLI BrainStorm
$11.21 /

+0.01 (+0.09%)

APT Alpha Pro Tech
$17.70 /

-0.05 (-0.28%)

AMC AMC Entertainment
$4.56 /

+0.275 (+6.42%)

MARK Remark Holdings
$2.30 /

-0.05 (-2.13%)

06/10/20 Roth Capital
Roth checks point to Kent Services as Remark Holdings distribution partner
05/27/20 Roth Capital
Wynn video 'clearly shows' Remark AI technology in use, says Roth Capital
07/15/19 Roth Capital
Sharecare liquidity event would help capitalize Remark AI business, says Roth Capital
APT Alpha Pro Tech
$17.70 /

-0.05 (-0.28%)

AMC AMC Entertainment
$4.56 /

+0.275 (+6.42%)

06/30/20 Imperial Capital
AMC Entertainment price target lowered to $4 from $6 at Imperial Capital
06/29/20 Credit Suisse
Cinemark downgraded to Neutral from Outperform at Credit Suisse
06/29/20 Credit Suisse
AMC Entertainment downgraded to Underperform from Neutral at Credit Suisse
06/17/20 Citi
AMC Entertainment price target raised to $4 from $1 at Citi
BCLI BrainStorm
$11.21 /

+0.01 (+0.09%)

BGS B&G Foods
$24.18 /

-0.23 (-0.94%)

06/12/20
Fly Intel: Top five analyst initiations
06/11/20 DA Davidson
B&G Foods initiated with a Neutral at DA Davidson
06/11/20 RBC Capital
B&G Foods initiated with a Sector Perform at RBC Capital
05/13/20
Fly Intel: Top five analyst upgrades
YCBD cbdMD
$1.88 /

-0.005 (-0.27%)

03/09/20 Cantor Fitzgerald
cbdMD price target lowered to $1.20 from $3.40 at Cantor Fitzgerald
11/07/19 Cantor Fitzgerald
Cantor Fitzgerald expects industry consolidation in consumer CBD wellness trend
11/07/19 Cantor Fitzgerald
cbdMD initiated with a Neutral at Cantor Fitzgerald
09/10/19 Benchmark
cbdMD initiated with a Speculative Buy at Benchmark
TTNP Titan Pharmaceuticals
$0.30 /

-0.0085 (-2.80%)

10/23/19 Maxim
Titan Pharmaceuticals upgraded to Buy from Hold at Maxim
10/23/19 Maxim
Titan Pharmaceuticals upgraded to Buy from Hold at Maxim
08/16/19
Titan Pharmaceuticals downgraded to Hold from Buy at Maxim
08/15/19 Maxim
Titan Pharmaceuticals downgraded to Hold from Buy at Maxim
PEI Pennsylvania REIT
$1.39 /

+0.03 (+2.21%)

03/26/20 RBC Capital
Cheesecake, AMC news highlight tenants financial stress, says RBC Capital
01/16/20 SunTrust
Pennsylvania REIT downgraded to Sell from Hold at SunTrust
01/15/20 SunTrust
Pennsylvania REIT downgraded to Sell from Hold at SunTrust
09/23/19 Citi
Pennsylvania REIT downgraded to Sell from Neutral at Citi
CRC California Resources
$1.27 /

+0.045 (+3.69%)

03/25/20 Imperial Capital
California Resources downgraded to In-Line from Outperform at Imperial Capital
03/17/20 Raymond James
California Resources downgraded to Market Perform from Outperform at Raymond James
03/17/20 Raymond James
California Resources downgraded to Market Perform from Outperform at Raymond James
03/09/20 BofA
California Resources downgraded to Underperform from Neutral at BofA
GRPN Groupon
$17.50 /

-0.59 (-3.26%)

06/18/20 Wedbush
Groupon price target lowered to $22 from $35 at Wedbush
06/18/20 Barclays
Groupon business model remains uncertain, says Barclays
06/17/20 DA Davidson
Groupon price target raised to $32 from $23 at DA Davidson
02/25/20 Ascendiant
Groupon price target lowered to $1.75 from $3.25 at Ascendiant
YCBD cbdMD
$1.88 /

-0.005 (-0.27%)

TTNP Titan Pharmaceuticals
$0.30 /

-0.0085 (-2.80%)

PEI Pennsylvania REIT
$1.39 /

+0.03 (+2.21%)

GRPN Groupon
$17.50 /

-0.59 (-3.26%)

CRC California Resources
$1.27 /

+0.045 (+3.69%)

BGS B&G Foods
$24.18 /

-0.23 (-0.94%)

BCLI BrainStorm
$11.21 /

+0.01 (+0.09%)

APT Alpha Pro Tech
$17.70 /

-0.05 (-0.28%)

AMC AMC Entertainment
$4.56 /

+0.275 (+6.42%)

  • 10
    Jan
GRPN Groupon
$17.50 /

-0.59 (-3.26%)

CRC California Resources
$1.27 /

+0.045 (+3.69%)

APT Alpha Pro Tech
$17.70 /

-0.05 (-0.28%)

AMC AMC Entertainment
$4.56 /

+0.275 (+6.42%)

PEI Pennsylvania REIT
$1.39 /

+0.03 (+2.21%)

MARK Remark Holdings
$2.30 /

-0.05 (-2.13%)

GRPN Groupon
$17.50 /

-0.59 (-3.26%)

CRC California Resources
$1.27 /

+0.045 (+3.69%)

BGS B&G Foods
$24.18 /

-0.23 (-0.94%)

APT Alpha Pro Tech
$17.70 /

-0.05 (-0.28%)

AMC AMC Entertainment
$4.56 /

+0.275 (+6.42%)

TTNP Titan Pharmaceuticals
$0.30 /

-0.0085 (-2.80%)

PEI Pennsylvania REIT
$1.39 /

+0.03 (+2.21%)

MARK Remark Holdings
$2.30 /

-0.05 (-2.13%)

GRPN Groupon
$17.50 /

-0.59 (-3.26%)

CRC California Resources
$1.27 /

+0.045 (+3.69%)

BGS B&G Foods
$24.18 /

-0.23 (-0.94%)

BCLI BrainStorm
$11.21 /

+0.01 (+0.09%)

APT Alpha Pro Tech
$17.70 /

-0.05 (-0.28%)

AMC AMC Entertainment
$4.56 /

+0.275 (+6.42%)

General news
FX Action: The dollar » 08:45
07/02/20
07/02
08:45
07/02/20
08:45

FX Action: The dollar was…

FX Action: The dollar was little changed following the data, where non-farm payrolls rose 4.8 M versus the consensus forecast of 3.090 M. The unemployment rate fell to 11.1% versus expectations for 12.3%. Jobless claims rose 1.427 M versus median expectations of 1.225 M, while the trade deficit widened a bit more than expected. EUR-USD idled near 1.1285, while USD-JPY headed over 107.55 from 107.45 into the data.

General news
U.S. nonfarm payrolls increased 4,800k in June » 08:45
07/02/20
07/02
08:45
07/02/20
08:45

U.S. nonfarm payrolls…

U.S. nonfarm payrolls increased 4,800k in June, better than expected, after the upwardly revised 2,699k (was 2,509k) bounce in May following the -20,787k (was -20,687k) collapse in April. The unemployment rate slide to 11.1% versus 13.3% (was 13.3%) previously, and April's 14.7%. The rate was at a 50-year low of 3.5% in February. The labor force rose another 1,705k after the prior 1,746k gain, with household employment up 4,940k versus 3,839k. The labor force participation rate rose to 61.5% versus 60.8%. Average hourly earnings declined another -1.2% versus -1.0% previously and 4.7% in April. Average weekly hours fell to 34.5 in June from 34.7 in May. Private payrolls climbed 4,767k (versus ADP's 2,369k) following the 3,232k (was 3,094k) increase in May The goods producing sector added 504k, with construction up 158k. Service sector jobs increased 4,263k. And leisure/hospitality added 2,088k. While there are still a lot of warts in the economy and the data, this is still a good report that will help underpin optimism on the recovery.

Hot Stocks
BRP Inc. to increase manufacturing capacity in Mexico » 08:44
07/02/20
07/02
08:44
07/02/20
08:44
DOOO

BRP Inc.

$42.00 /

-0.67 (-1.57%)

BRP announced that it is…

BRP announced that it is increasing its manufacturing capacity with the construction of a new facility in Mexico to meet demand for its off-road vehicles business. This expansion of BRP's production facilities is intended to help keep pace with the increased demand for Can-Am side-by-side vehicles experienced in recent years. After a temporary slowdown due to COVID-19, retail sales went up by over 35% in May, compared to the previous year, and the trend continued in June. The planned facility will be located in Juarez and represents an investment of an estimated C$185M and would result in the creation of up to 1,000 permanent jobs. BRP's total capital expenditure for FY21 is now expected to be in a range of C$275M to C$300M. Site planning and construction are scheduled to begin within the next months, and the plant is expected to be ready for operation by Fall 2021. This new plant, combined with the company's two off-road manufacturing facilities in Juarez, will create positive operational synergies and efficiencies.

ShowHide Related Items >><<
DOOO BRP Inc.
$42.00 /

-0.67 (-1.57%)

DOOO BRP Inc.
$42.00 /

-0.67 (-1.57%)

06/24/20 RBC Capital
BRP Inc. price target raised to C$60 from C$52 at RBC Capital
06/17/20 Stifel
BRP Inc. initiated with a Buy at Stifel GMP
05/29/20 TD Securities
BRP Inc. price target raised to C$56 from C$49 at TD Securities
05/29/20 BMO Capital
BRP Inc. price target raised to C$45 from C$29 at BMO Capital
Hot Stocks
Aquestive CEO sees near-term value driven by CNS/epilepsy franchise » 08:43
07/02/20
07/02
08:43
07/02/20
08:43
AQST

Aquestive Therapeutics

$4.75 /

-0.11 (-2.26%)

Aquestive Therapeutics…

Aquestive Therapeutics (AQST) is a pharmaceutical company committed to developing and commercializing products to address unmet medical needs. In an exclusive interview with The Fly, Aquestive President and CEO Keith Kendall discussed the company and potential key value drivers: "The company has certainly been negatively impacted by a number of tangential events that are not in our control and, in some cases, not central to the key value drivers of the company. Aquestive is a fully integrated pharmaceutical company with multiple approved products, and additional pipeline candidates in development. Near-term value will be driven by the CNS/epilepsy franchise comprised of Sympazan, already launched, and Libervant, with its NDA currently pending at the FDA. Additionally, significant value has the potential to be created if we are successful in the development and launch of AQST-108 sublingual epinephrine, a potentially significant disruptive change to the historically injectable therapies currently available. Moreover, we believe that the company has significant opportunity to continue to provide innovative therapies in complex conditions beyond the programs currently in our pipeline, and we will consider augmenting our PharmFilm technology and know-how with other technologies in order to expand what we do for patients in our targeted therapeutic areas and other disease states. We expect that we will add other products to our pipeline over time, with a focus on under-treated conditions where our innovative drug delivery technology and know-how can create significant value for the patient." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company.

ShowHide Related Items >><<
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

  • 13
    Dec
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

Hot Stocks
Kitov Pharmaceuticals CEO reports over $60M in cash by the end of June » 08:43
07/02/20
07/02
08:43
07/02/20
08:43
KTOV

Kitov Pharmaceuticals

$0.90 /

-0.215 (-19.28%)

Kitov Pharma provided the…

Kitov Pharma provided the following letter to shareholders from its CEO Isaac Israel. "Following our recently closed $35M financing, we believe we have successfully completed our evolution to an oncology focused biotechnology company, and wanted to provide our shareholders and other stakeholders with an update on our business and strategic plans. As of the end of June 2020, we had over $60M in cash, which we believe positions us well to conduct the two clinical studies we intend to initiate this year, and provides us with the resources to expand these development programs, as appropriate, as well as potentially acquire additional promising drug candidates that we may identify to further expand our pipeline. Moreover, we continue to support our distribution partners for CONSENSI indicated for the simultaneous treatment of hypertension and osteoarthritis pain in the U.S. and the Far East. Importantly, following the recent launch of CONSENSI in the U.S., this drug is expected to begin generating royalty revenue for Kitov this year. With this launch underway, our strategic focus has shifted to the development of innovative therapeutics to treat cancer patients with significant unmet medical needs. We are focused on building a pipeline of first-in-class oncology assets based on our three core values of Innovation - we have assembled a team of world-class oncology drug developers, Collaboration - we strive to establish beneficial relationships with our partners to best progress our mission, and Agility - we are focused on advancing our pipeline as expeditiously as possible. Our emerging oncology pipeline currently consists of CM24, a monoclonal antibody targeting CEACAM1, a novel immune checkpoint that supports tumor immune evasion and survival through multiple pathways, in patients with advanced cancer, and NT219, a dual inhibitor, novel small molecule targeting IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat cancers. In addition, with a strong balance sheet that includes no debt, we have the flexibility to enhance our growth through smart acquisitions and/or in-licensing activity that we may identify in our core focus area of oncology. We expect to identify promising drug candidates with unique differentiation that have the potential to create exciting new treatment paradigms for the benefit of cancer patients. Our core objective is to become a recognized leader in the oncology field and to make a significant impact on patients' lives. An important aspect of our strategy is to collaborate with third-parties. As a result of our recent financing activity, our current balance sheet provides us with the ability to maximize the value of the strategic opportunities that we are pursuing. We look forward to providing you with further updates on these ongoing activities as events warrant."

ShowHide Related Items >><<
KTOV Kitov Pharmaceuticals
$0.90 /

-0.215 (-19.28%)

Recommendations
Lumentum price target raised to $107 from $96 at MKM Partners » 08:42
07/02/20
07/02
08:42
07/02/20
08:42
LITE

Lumentum

$80.36 /

-1.02 (-1.25%)

MKM Partners analyst…

MKM Partners analyst Michael Genovese raised the firm's price target on Lumentum to $107 from $96 and keeps a Buy rating on the shares. The analyst is citing the demand strength in Optical Comms, with his checks suggesting strong orders. Genovese adds that the drivers of Lumentum's Datacom product strength include a 400G Datacom market inflection, which looks sustainable, as well as the 5G front-haul and back-haul in China.

ShowHide Related Items >><<
LITE Lumentum
$80.36 /

-1.02 (-1.25%)

LITE Lumentum
$80.36 /

-1.02 (-1.25%)

05/21/20 Rosenblatt
Rosenblatt sees little impact on Lumentum, NeoPhotonics' current sales to Huawei
05/06/20 Craig-Hallum
Lumentum price target raised to $100 from $95 at Craig-Hallum
05/06/20 Piper Sandler
Lumentum price target raised to $100 from $95 at Piper Sandler
05/05/20 Raymond James
Lumentum price target raised to $97 from $90 at Raymond James
LITE Lumentum
$80.36 /

-1.02 (-1.25%)

LITE Lumentum
$80.36 /

-1.02 (-1.25%)

LITE Lumentum
$80.36 /

-1.02 (-1.25%)

LITE Lumentum
$80.36 /

-1.02 (-1.25%)

Hot Stocks
Kitov expects cash runway to support activities into at least 2024 » 08:41
07/02/20
07/02
08:41
07/02/20
08:41
KTOV

Kitov Pharmaceuticals

$0.90 /

-0.215 (-19.28%)

CEO Isaac Israel said,…

CEO Isaac Israel said, "I would like to provide an update on our current pipeline and CONSENSI. On May 14, 2020, we announced that the positive results of a previously reported Phase 1 trial of CM24 were presented in a poster presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program. These Phase 1 results are encouraging and indicate that CM24 at higher doses warrants further evaluation in a larger clinical study. Importantly, pharmacokinetic modelling suggests that higher doses of CM24 of up to 20mg/kg administered every two weeks would be required for target saturation. We look forward to the anticipated initiation of our planned Phase 1/2 clinical trial to evaluate the combination of CM24 with the PD-1 inhibitor, nivolumab, to be conducted in collaboration with Bristol Myers Squibb, which we expect to initiate in the second half of this year. In order to maximize the potential of the trial to demonstrate a strong efficacy signal, we intend to include expansion cohorts that will follow the dose escalating phase: an expansion cohort in non-small cell lung cancer patients, and an additional expansion cohort in pancreatic cancer patients. This new arm of the trial in pancreatic cancer patients is designed to evaluate the CEACAM1/PD-1 combination in addition to standard of care chemotherapy. On May 22, 2020, we announced that the U.S. Food and Drug Administration had accepted our Investigational New Drug application to conduct a Phase 1/2 clinical trial of NT219. The study is designed to evaluate NT219 as a monotherapy treatment for advanced solid tumors and in combination with cetuximab, an epithelial growth factor receptor blocking monoclonal antibody, for the treatment of recurrent or metastatic solid tumors and head and neck cancer or colorectal adenocarcinoma. Based on the encouraging pre-clinical data generated in various studies with NT219, as both monotherapy and in combination with cetuximab, we believe this promising drug candidate has the potential to be a safe and effective therapy for multiple hard-to-treat cancers. In addition to U.S. clinical sites, and in order to mitigate a potential COVID-19 pandemic-related slowdown in patient recruitment into the study, we are also including additional clinical sites in Canada. The primary objectives of the open-label Phase 1/2 trial are to evaluate safety, assess pharmacokinetics, identify the appropriate dose to be studied in the Phase 2 portion, and establish preliminary efficacy of NT219. The Phase 1 portion of the study will encompass a dose escalation evaluation of NT219 monotherapy administered in patients with refractory advanced solid tumors. A second cohort of patients, with either recurrent or metastatic squamous cell carcinoma of the head and neck or colorectal adenocarcinoma, will be dosed with NT219, dose escalated, in combination with cetuximab. Upon completion of the Phase 1 monotherapy and combination dose escalation portion of the trial, we plan to commence the expansion Phase 2 components of the study at the recommended Phase 2 dose of NT219 in combination with cetuximab. In addition, based on the data obtained in the Phase 1 monotherapy portion, we intend to pursue an expansion Phase 2 study in a yet to be defined indication for NT219 as monotherapy. The principal investigator of the Phase 1/2 study is Dr. Ezra Cohen, Chief, Division of Hematology-Oncology at the University of California San Diego, and a distinguished key opinion leader. We expect to activate up to eight sites in the U.S. and Canada over the next few months and that our first clinical site will be initiated shortly. On May 20, 2020, we announced the U.S. commercial launch of CONSENSI, a fixed-dose combination of celecoxib and amlodipine besylate, designed for the simultaneous treatment of hypertension and osteoarthritis pain. CONSENSI is being sold in the U.S. by Burke Therapeutics, the marketing partner of Kitov's U.S. distributor, Coeptis Pharmaceuticals. Burke Therapeutics' sales team is growing steadily, and is expected to soon include about 50 sales representatives, with plans to increase this number further. We believe the team is highly-motivated to introduce this once-a-day treatment for hypertension and osteoarthritis pain in the U.S. market. In addition, we believe Burke is taking the necessary actions to overcome the short-term challenges imposed by the COVID-19 pandemic and we look forward to sales beginning to ramp up in the next few months, which will result in royalty revenue to us of 20% of sales, pursuant to our marketing and distribution agreement with Coeptis. According to the agreement for CONSENSI, Kitov is eligible to receive up to $99.5M in milestone and reimbursement payments, in addition to royalties. We expect to receive aggregate milestone and royalty revenues of between $28M and $36M from 2020 through 2022. In summary, we look forward to further advancing our commercial and clinical activities by leveraging our strong cash position. Our current cash runway is expected to support our currently planned activities into at least 2024, beyond multiple anticipated clinical milestones, and we believe we are well-funded to execute our strategic plans."

ShowHide Related Items >><<
KTOV Kitov Pharmaceuticals
$0.90 /

-0.215 (-19.28%)

General news
International Trade Balance Level data reported » 08:40
07/02/20
07/02
08:40
07/02/20
08:40

May International Trade…

May International Trade Balance Level at -$54.6B vs consensus of -$53.0B

General news
Jobless Claims data reported » 08:40
07/02/20
07/02
08:40
07/02/20
08:40

Week of 6/27 Jobless…

Week of 6/27 Jobless Claims at 1,427K vs. consensus of 1,400K

Hot Stocks
Jaguar Health submits regulatory filing to CVM to support approval of Canalevia » 08:39
07/02/20
07/02
08:39
07/02/20
08:39
JAGX

Jaguar Health

$0.48 /

-0.0002 (-0.04%)

Jaguar Health announced…

Jaguar Health announced that it has submitted to the FDA's Center for Veterinary Medicine, or CVM, the final major regulatory filing to support approval of its oral plant-based drug candidate Canalevia to treat exercise-induced diarrhea, or EID, in dogs. Working dogs, including search and rescue, military and sled dogs, often suffer diarrhea as a result of engaging in long periods of intense, off-leash exercise. In addition to EID, Jaguar is also seeking conditional approval to market Canalevia for chemotherapy-induced diarrhea, or CID, in dogs.

ShowHide Related Items >><<
JAGX Jaguar Health
$0.48 /

-0.0002 (-0.04%)

JAGX Jaguar Health
$0.48 /

-0.0002 (-0.04%)

11/18/19 H.C. Wainwright
Jaguar Health price target lowered to $3 from $10 at H.C. Wainwright
09/12/19 Ladenburg
Jaguar Health initiated with a Buy at Ladenburg
JAGX Jaguar Health
$0.48 /

-0.0002 (-0.04%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.